Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KaloBios Pharmaceuticals and Sanofi Pasteur have released data from the initial clinical studies with KB001, a new antibody fragment against PcrV on Pseudomonas aeruginosa (Pa), bioengineered by KaloBios Pharmaceuticals and partnered by Sanofi Pasteur.
Subscribe to our email newsletter
The data demonstrated positive therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonised with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.
KaloBios Pharmaceuticals and Sanofi Pasteur have presented the findings in multiple sessions at the American Thoracic Society Meeting being held from May 14-19 in New Orleans, LA.
Tillman Pearce, chief medical officer of KaloBios Pharmaceuticals, said: “By binding to and blocking the function of PcrV, an important element of the type-three secretion system associated with Pa virulence, KB001 offers a new approach in the treatment of serious Pa infections.
“The data being presented at ATS not only highlight the therapeutic potential for KB001 in preventing Pa pneumonia in mechanically ventilated patients and for treating Pa lung infection in patients with cystic fibrosis, but the fact that KB001 may represent an alternative to the use of antibiotics which are often rendered ineffective in these settings due to resistance development.”